Dr. Bergmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6507 Harrison Avenue
Suite E
Cincinnati, OH 45247Phone+1 513-661-3566Fax+1 513-661-6469
Clinical Expertise
- Dry eye, Cataracts, Diabetes, Laser general surgery, Clinical research, Glaucoma, No stitch, No patch, No shot cataract implant surgery. External eye disease, Diabetic eye exams, Eye research studies, Office lid lesion removal, Laser surgery-glaucoma & after cataract
Education & Training
- Detroit Medical Center/Wayne State UniversityFellowship, Cornea, External Diseases, and Refractive Surgery, 1987 - 1987
- Cullen Eye Institute-BaylorFellowship, Cataract Fellowship, 1986 - 1986
- University of ToledoResidency, Ophthalmology, 1983 - 1986
- Jewish Hospital of CincinnatiInternship, Internal Medicine, 1982 - 1983
- Wright State University Boonshoft School of MedicineClass of 1982
Certifications & Licensure
- OH State Medical License 1983 - 2025
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Top Doctor Cincinnati Magazine, 2013, 2017, 2021
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain Start of enrollment: 2016 Jun 01
Publications & Presentations
PubMed
- 4 citationsPhase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.John D. Sheppard, M.T. Bergmann, Barry A. Schechter, Jodi Luchs, Abayomi Ogundele
Clinical Ophthalmology. 2021-01-12 - 4 citationsPooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitisEugene B McLaurin, M.T. Bergmann, Abhijit Narvekar, Adeniyi Adewale, Paul J Gomes
Clinical Ophthalmology. 2017-06-08 - 17 citationsEfficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.Gail Torkildsen, Abhijit Narvekar, M.T. Bergmann
Clinical Ophthalmology. 2015-09-14
Research History
- Principal InvestigatorPrincipal Investigator for several eye drop studies related to allergy, cataract surgery, dry eyes, conjunctivitis, and glaucoma.2007 - 2017
Professional Memberships
- Fellow
External Links
- Cincinnati Eye Institute http://Cincinnatieye.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: